Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Operating Expenses of $11.7 million for Q1 2026, down 41.04% year-over-year from $19.9 million in Q1 2025, and up 8.81% quarter-over-quarter from $10.8 million in Q4 2025.
Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Operating Expenses history runs 5 years deep, the most recent figure standing at $11.7 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 41.04% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $48.7 million (down 25.65% YoY), while the FY2025 annual figure was $56.9 million, up 4.47% from the prior year.
- Operating Expenses for Q1 2026 stood at $11.7 million, up from $10.8 million in the prior quarter.
- The five-year high for Operating Expenses was $19.9 million in Q1 2025, with the low at $6.8 million in Q1 2023.
- The 5-year median for Operating Expenses is $10.0 million (2023), against an average of $11.1 million.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 126.56% in 2025, then sank 41.04% in 2026.
- Sagimet Biosciences' Operating Expenses stood at $7.4 million in 2022, then advanced by 28.13% to $9.5 million in 2023, then jumped by 92.21% to $18.2 million in 2024, then plunged by 40.84% to $10.8 million in 2025, then rose by 8.81% to $11.7 million in 2026.
- Business Quant data shows SGMT's Operating Expenses at $11.7 million in Q1 2026, $10.8 million in Q4 2025, and $14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 15.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.82 Mn |
| Mar 31, 2026 | 11.71 Mn |
| Dec 31, 2025 | 10.77 Mn |
| Sep 30, 2025 | 14.33 Mn |
| Jun 30, 2025 | 11.93 Mn |
| Mar 31, 2025 | 19.87 Mn |
| Dec 31, 2024 | 18.20 Mn |
| Sep 30, 2024 | 16.90 Mn |
| Jun 30, 2024 | 10.59 Mn |
| Mar 31, 2024 | 8.77 Mn |
| Dec 31, 2023 | 9.47 Mn |
| Sep 30, 2023 | 9.45 Mn |
| Jun 30, 2023 | 7.06 Mn |
| Mar 31, 2023 | 6.77 Mn |
| Dec 31, 2022 | 7.39 Mn |
| Sep 30, 2022 | 7.69 Mn |
| Jun 30, 2022 | 7.24 Mn |